ATL-001b: Porphyria Cutanea Tarda (PCT)
Categoría
Drugs National Companies
Tipo de registro
Biotech Sanitaria
Nombre socio
Producto / Servicio
ATL-001b: Porphyria Cutanea Tarda (PCT)
Tipo
Biodrugs/ Drugs
Area terapéutica
Enfermedades genéticas y raras
Propiedades/Indicación
PCT is the most common of porphyries and it encompasses a group of acquired and familial disorders in which activity of the uroporphyrinogen decarboxylase (UROD) is deficient. In Atlas, we are currently exploring the possibility of applying pharmacological chaperones to improve heme homeostasis in PCT patients. This project is at the lead validation of therapeutic chaperones.
Fase de desarrollo
R&D
Fases desarrolladas en España
R&D